SAN DIEGO, March 4, 2014 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical drug formulations, today announced that Imprimis CEO Mark L. Baum is scheduled to participate at two growth investor conferences during the month of March.
On Monday, March 10, 2014, Mr. Baum is scheduled to present at the 26th Annual ROTH Conference at 5:30 pm PT at the Ritz-Carlton Laguna Niguel, California and will be available for one-on-one meetings for conference attendees through the conference request process. The presentation will also be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.imprimispharma.com.
Later that week on Wednesday, March 12, 2014, Mr. Baum is scheduled to participate at the Northland Capital Markets 2014 Growth Conference at the Omni Berkshire Place Hotel located at 21 East 52nd Street New York, NY, and will be available for one one-on-one meetings for conference attendees. Any other meeting requests outside of these two appearances can be directed to the Imprimis IR Team at firstname.lastname@example.org.
ABOUT IMPRIMIS PHARMACEUTICALS
San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a specialty pharmaceutical company focused on the development and commercialization of proprietary and novel sterile and topical drug formulations. Certain of Imprimis' patent-pending technologies and formulations are available today and are being prescribed by physicians. For more information, please visit www.imprimispharma.com or www.GoDropless.com.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its formulations and technologies in a timely manner or at all; physician interest in prescribing its formulations; Imprimis' ability to close the acquisition of Pharmacy Creations, LLC and realize the expected benefits of the transaction; its ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of its formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for its technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
MEDIA CONTACT: Jen Carroll
SOURCE Imprimis Pharmaceuticals, Inc.